Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrosolv in Grass Pollen Induced Allergic Rhinoconjunctivitis
NCT04532710Phase 2Completed
- Sponsor
- Marinomed Biotech
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tacrolimus in allergic rhinoconjunctivitis (ARC), sponsored by Marinomed Biotech. Started Aug 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT04532710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532710.